New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

Author： Blandini Fabio   Armentero Marie-Therese  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.2, 2012-02, pp. : 153-168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias

By  

Current Neuropharmacology, Vol. 14, Iss. 5, 2016-06 ,pp. : 481-493

Bentham Science Publishers

Access to resources Recommend Favorite

Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. : 1101-1113

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of acute and repeated treatment with a novel dopamine D 2 receptor ligand on l-DOPA-induced dyskinesias in MPTP monkeys

By Tahar A.H.   Ekesbo A.   Gregoire L.   Bangassoro E.   Svensson K.A.   Tedroff J.   Bedard P.J.  

European Journal of Pharmacology, Vol. 412, Iss. 3, 2001-02 ,pp. : 247-254

Elsevier

Access to resources Recommend Favorite

MK801 influences l-DOPA-induced dopamine release in intact and hemi-parkinson rats

By Jonkers N.   Sarre S.   Ebinger G.   Michotte Y.  

European Journal of Pharmacology, Vol. 407, Iss. 3, 2000-11 ,pp. : 281-291

Elsevier

Access to resources Recommend Favorite

Mitophagy and Disease: New Avenues for Pharmacological Intervention

By  

Current Pharmaceutical Design, Vol. 17, Iss. 20, 2011-07 ,pp. : 2056-2073

Bentham Science Publishers

Access to resources Recommend Favorite